ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of “Moderate Buy” from Analysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $7.1429.

PRQR has been the subject of a number of research reports. Chardan Capital reaffirmed a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Tuesday, November 4th. Zacks Research upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Thursday, January 22nd.

ProQR Therapeutics Trading Down 2.0%

Shares of PRQR opened at $1.47 on Tuesday. The firm has a fifty day simple moving average of $1.92 and a two-hundred day simple moving average of $2.15. The firm has a market cap of $154.66 million, a PE ratio of -3.13 and a beta of 0.20. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $3.10.

Institutional Trading of ProQR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRQR. Osaic Holdings Inc. increased its holdings in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the last quarter. Moody Lynn & Lieberson LLC bought a new position in ProQR Therapeutics during the fourth quarter valued at approximately $50,000. Fifth Third Bancorp purchased a new position in ProQR Therapeutics during the 3rd quarter valued at approximately $64,000. Jane Street Group LLC increased its stake in ProQR Therapeutics by 699.3% in the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 79,720 shares during the last quarter. Finally, Vontobel Holding Ltd. increased its stake in ProQR Therapeutics by 76.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 63,979 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 27,722 shares during the last quarter. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.